Chemotherapy-induced peripheral neuropathy

Osmol Therapeutics Appoints Ron Weitzman, M.D., as Interim Chief Medical Officer

Retrieved on: 
Monday, March 4, 2024

NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Osmol Therapeutics, a privately held clinical-stage biopharmaceutical company focused on developing preventative treatments for chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI), today announced that it has appointed Ron Weitzman, M.D., as interim Chief Medical Officer, replacing Arthur DeCillis, M.D., who is joining Osmol’s Scientific Advisory Board.

Key Points: 
  • NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Osmol Therapeutics, a privately held clinical-stage biopharmaceutical company focused on developing preventative treatments for chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI), today announced that it has appointed Ron Weitzman, M.D., as interim Chief Medical Officer, replacing Arthur DeCillis, M.D., who is joining Osmol’s Scientific Advisory Board.
  • “We are pleased to welcome Ron, with his significant oncology drug development expertise, to the Osmol team,” said Bob Linke, MBA, President and CEO of Osmol Therapeutics.
  • Ron Weitzman, M.D., has held leadership roles at various global biopharmaceutical companies, including Tango Therapeutics, Exelixis, Genentech and Novartis.
  • Most recently he served as Chief Medical Officer at Tango Therapeutics, where he oversaw development of multiple oncology drugs, including three Investigational New Drug (IND) applications, while leading the clinical and clinical operations teams.

Bexion Pharmaceuticals, Inc. Appoints Dr. Tariq Arshad as Chief Medical Officer

Retrieved on: 
Wednesday, February 28, 2024

COVINGTON, Ky., Feb. 28, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced the appointment of Tariq Arshad, MD, MBA as Chief Medical Officer.

Key Points: 
  • COVINGTON, Ky., Feb. 28, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced the appointment of Tariq Arshad, MD, MBA as Chief Medical Officer.
  • Dr. Arshad is an oncologist with more than 25 years of experience and a successful track record of strategic planning, clinical development, and commercialization.
  • "We are thrilled to appoint Dr. Arshad as Bexion's Chief Medical Officer," said Scott Shively, Bexion's Chief Executive Officer.
  • Dr. Arshad previously led medical strategies for blockbuster biologic therapies approved for clinical use in major immunology indications and other groundbreaking therapies as Head of Medical Affairs for Immunology at Sanofi, and he served as Chief Medical Officer and Head of Clinical Research at Humanigen, developing novel immune-oncology therapies.

Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

Retrieved on: 
Tuesday, January 23, 2024

The research article, titled “ Discovery and preclinical evaluation of a novel inhibitor of FABP5, ART26.12, effective in Oxaliplatin-induced Peripheral Neuropathy ,” highlights Artelo’s pre-clinical asset, ART26.12, and its potential ability to treat and prevent Oxaliplatin-Induced Peripheral Neuropathy (OIPN) in a series of separate studies.

Key Points: 
  • The research article, titled “ Discovery and preclinical evaluation of a novel inhibitor of FABP5, ART26.12, effective in Oxaliplatin-induced Peripheral Neuropathy ,” highlights Artelo’s pre-clinical asset, ART26.12, and its potential ability to treat and prevent Oxaliplatin-Induced Peripheral Neuropathy (OIPN) in a series of separate studies.
  • ART26.12 is a Fatty Acid Binding Protein 5 (FABP5) inhibitor in development for the treatment of chemotherapy-induced peripheral neuropathy (CIPN), a type of neuropathic pain caused by chemotherapy as well as non-chemotherapy cancer treatments such as immunomodulating drugs.
  • Artelo has conducted multiple pre-clinical studies in painful neuropathies, including diabetic neuropathy, paclitaxel-induced peripheral neuropathy, and OIPN, the latter two of which has no FDA-approved treatment.
  • The Company previously reported a positive pre-IND (investigational new drug) meeting with the Food and Drug Administration (FDA) and anticipates filing the IND for ART26.12 in the first half of 2024.

Bexion Pharmaceuticals, Inc. Announces Poster Presentation at ASCO GI 2024

Retrieved on: 
Tuesday, January 16, 2024

COVINGTON, Ky., Jan. 16, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced a Trials in Progress poster presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), being held January 18-20, 2024, in San Francisco, CA.

Key Points: 
  • COVINGTON, Ky., Jan. 16, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced a Trials in Progress poster presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), being held January 18-20, 2024, in San Francisco, CA.
  • Poster details are included below.
  • "We are excited to present our ongoing trial of BXQ-350 in mCRC during the 2024 ASCO GI Symposium" said Scott Shively, CEO and President of Bexion Pharmaceuticals.
  • "BXQ-350 in combination with FOLFOX and bevacizumab offers a unique opportunity to improve outcomes for 1st line patients with mCRC.

Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12

Retrieved on: 
Monday, January 8, 2024

“We look forward to working with Worldwide once we obtain approval from the FDA to advance ART16.12 into Phase 1 clinical development,” commented Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.

Key Points: 
  • “We look forward to working with Worldwide once we obtain approval from the FDA to advance ART16.12 into Phase 1 clinical development,” commented Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.
  • “With Worldwide’s extensive experience in the neurology space and successful track record of assisting companies progress through trials, we believe we are well positioned to leverage ART26.12’s positive profile observed in multiple animal models of painful neuropathies to progress to human studies.”
    “We are excited to partner with the Artelo Biosciences team on their important advancement with ART26.12,” stated Peter Benton, President and Chief Executive Officer of Worldwide Clinical Trials.
  • Artelo has conducted five pre-clinical studies in painful neuropathies, including diabetic neuropathy and chemotherapy-induced peripheral neuropathy, the latter of which has no FDA-approved treatment.
  • The Company previously reported a positive pre-IND (investigational new drug) meeting with the Food and Drug Administration and anticipates filing the IND for ART26.12 in the first half of this year.

Bexion Pharmaceuticals, Inc. to Present at Biotech Showcase 2024

Retrieved on: 
Friday, January 5, 2024

COVINGTON, Ky., Jan. 5, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company will present at Biotech Showcase 2024 during the J.P. Morgan 42nd Annual Healthcare Conference week. Biotech Showcase 2024 will be held in-person, from January 8-10, 2024, in San Francisco, CA.

Key Points: 
  • COVINGTON, Ky., Jan. 5, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company will present at Biotech Showcase 2024 during the J.P. Morgan 42nd Annual Healthcare Conference week.
  • Biotech Showcase 2024 will be held in-person, from January 8-10, 2024, in San Francisco, CA.
  • Scott Shively, CEO and President of Bexion Pharmaceuticals, and Joyce LaViscount, Chief Financial Officer of Bexion Pharmaceuticals, will attend the conference.
  • Additionally, the Bexion management team will host one-on-one meetings with potential investors in San Francisco from January 8-11, 2024.

Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting

Retrieved on: 
Monday, December 4, 2023

CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a poster presentation at the 62nd Annual Meeting for the American College of Neuropsychopharmacology (ACNP). The conference is being held from December 3rd to 6th, 2023.

Key Points: 
  • CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a poster presentation at the 62nd Annual Meeting for the American College of Neuropsychopharmacology (ACNP).
  • The poster discussed the potential utility of TRV045 for the treatment of chemotherapy-induced peripheral neuropathy (CIPN) using an established nonclinical model.
  • CIPN is a nerve-damaging side effect of antineoplastic agents and occurs in approximately 70% of oncology patients undergoing chemotherapy.
  • Oral administration of TRV045 reduced mechanical and cold stimulus-evoked nociception in a dose-related manner in a mouse model of CIPN.

New Research in JNCCN Suggests a Simple and Inexpensive Option for Reducing a Major Chemotherapy Side-Effect

Retrieved on: 
Tuesday, November 7, 2023

PLYMOUTH MEETING, Pa., Nov. 7, 2023 /PRNewswire/ -- New research in the November 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network suggests that patients who have insufficient levels of vitamin D before starting paclitaxel treatment are more likely to experience peripheral neuropathy. According to an analysis of 1,191 patients with early-stage breast cancer—using data collected in the SWOG S0221 study—20.7% of patients with vitamin D deficiency experienced at least a grade 3 level of chemotherapy-induced peripheral neuropathy (CIPN), compared to 14.2% of those with sufficient vitamin D levels. The researchers also found that inducing vitamin D deficiency in an accompanying mice model study caused neurotoxicity-like symptoms.

Key Points: 
  • The researchers also found that inducing vitamin D deficiency in an accompanying mice model study caused neurotoxicity-like symptoms.
  • "There are barely any negative consequences that come from taking steps to increase vitamin D levels.
  • The researchers also noted that it is well-established that vitamin D deficiency is more common in self-reported Black patients.
  • This research holds the promise of shedding future light on the mechanisms underlying CIPN and the potential identification of biomarkers that could predict CIPN incidence."

Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023

Retrieved on: 
Thursday, November 2, 2023

Another poster will present work on Artelo’s proprietary cocrystal of cannabidiol and tetramethylpyrazine, ART12.11, which has demonstrated improved efficacy and bioavailability compared to cannabidiol alone in a model of anxiety and depression.

Key Points: 
  • Another poster will present work on Artelo’s proprietary cocrystal of cannabidiol and tetramethylpyrazine, ART12.11, which has demonstrated improved efficacy and bioavailability compared to cannabidiol alone in a model of anxiety and depression.
  • “We are very pleased to have two of our programs being featured at this year’s conference,” commented Dr. Andrew Yates, Chief Scientific Officer at Artelo Biosciences.
  • ART26.12 has demonstrated a positive effect in numerous animal models of painful neuropathies, including chemotherapy-induced peripheral neuropathy (CIPN) and diabetic neuropathy.
  • For more information about the conference, please visit Neuroscience 2023 .

Recent Research Continues to Support the Benefits of Massage Therapy for Cancer Patients

Retrieved on: 
Monday, October 23, 2023

EVANSTON, Ill., Oct. 23, 2023 /PRNewswire/ -- It's Breast Cancer Awareness Month, and the American Massage Therapy Association (AMTA) is sharing the latest research on the benefits of massage therapy for cancer patients.

Key Points: 
  • EVANSTON, Ill., Oct. 23, 2023 /PRNewswire/ -- It's Breast Cancer Awareness Month, and the American Massage Therapy Association (AMTA) is sharing the latest research on the benefits of massage therapy for cancer patients.
  • Explore recent studies on how massage therapy can ease symptoms and empower cancer patients.
  • During National Massage Therapy Awareness Week®, explore recent studies on the ways massage therapy can ease symptoms and make an important difference for those coping with cancer.
  • From pain management to relieving lymphedema, massage therapy has been proven to be an important part of integrative care for cancer patients.